Introduction:
The article discusses how patent protection can be secured for biosimilars, which are generic versions of biologic therapeutics. It highlights the importance of patent thickets in biosimilar development and the challenges faced in upgrading the manufacturing process for new indications. The article also addresses the concerns of investors regarding scale and the need for optimization in the manufacturing process to capture market share and extend patent protection.
- The market potential of new indications for existing biologic therapeutics can be hindered by technical challenges, but recent advances in QTL-enabled recombinant protein projects offer new opportunities for creating additional patent protection.
- Using old manufacturing processes for new indications can lead to higher costs, delays, and inefficiencies. Upgrading the manufacturing process for biosimilars can result in more affordable prices and market dominance.
- Investors are concerned about the scalability of biosimilar production, and sticking to outdated manufacturing approaches can undermine the feasibility of recombinant protein projects.
- Optimization of the manufacturing process, particularly through QTL technology, can provide tailored solutions and extended patent protection for biosimilar products.
Conclusion:
In order to secure patent protection for biosimilars, it is crucial to overcome technical challenges, upgrade the manufacturing process, and optimize key aspects of production. QTL technology offers a powerful tool for capturing market share and extending patent protection. By utilizing these strategies, biosimilar developers can stay competitive and attract investors while meeting customer demand.
